Bavarian Nordic A/S BVNKF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $22.60
- Day Range
- $18.72–18.72
- 52-Week Range
- $17.45–32.05
- Bid/Ask
- $19.85 / $25.35
- Market Cap
- $1.46 Bil
- Volume/Avg
- 565 / 387
Key Statistics
- Price/Earnings (Normalized)
- 4.89
- Price/Sales
- 1.40
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Bavarian Nordic A/S is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora and Vivotif.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,379
- Website
- https://www.bavarian-nordic.com
Comparables
Valuation
|
Metric
|
BVNKF
|
GUBRA
|
NYKD
|
|---|---|---|---|
Price/Earnings (Normalized) | 4.89 | 402.97 | — |
Price/Book Value | 0.95 | 10.05 | 2.59 |
Price/Sales | 1.40 | 21.90 | 30.43 |
Price/Cash Flow | 3.71 | — | — |
Price/Earnings
BVNKF
GUBRA
NYKD
Financial Strength
|
Metric
|
BVNKF
|
GUBRA
|
NYKD
|
|---|---|---|---|
Quick Ratio | 1.33 | 6.40 | 7.91 |
Current Ratio | 1.94 | 6.45 | 8.04 |
Interest Coverage | 14.67 | −8.73 | −235.75 |
Quick Ratio
BVNKF
GUBRA
NYKD
Profitability
|
Metric
|
BVNKF
|
GUBRA
|
NYKD
|
|---|---|---|---|
Return on Assets (Normalized) | 15.06% | −7.38% | −19.18% |
Return on Equity (Normalized) | 22.77% | −10.20% | −26.31% |
Return on Invested Capital (Normalized) | 21.52% | −8.49% | −30.96% |
Return on Assets
BVNKF
GUBRA
NYKD
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wsjqpkbfnz | Ppxh | $559.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wcmzpmlc | Rxxzbv | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Txklpvhv | Qwvcyg | $103.3 Bil | |
MRNA
| Moderna Inc | Vkkgpwph | Glyvm | $48.1 Bil | |
ARGX
| argenx SE ADR | Jvmdzmhd | Lxs | $23.1 Bil | |
BNTX
| BioNTech SE ADR | Tdybbrnn | Ffgq | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kymlvdqj | Fyzbfjk | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fnyftctpb | Kshsxm | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rqlhrmwvq | Pjdkd | $12.7 Bil | |
INCY
| Incyte Corp | Ypnrjdlf | Brwlfz | $11.9 Bil |